BiotechTube
Engage Bio

Engage Bio

San Diego, United States· Est.
engagebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

Engage Bio is an early-stage biotech developing the Tethosome platform, a novel non-viral DNA delivery technology. The platform co-delivers therapeutic DNA and mRNA encoding a proprietary Tethosome protein, which localizes DNA to the nucleus to boost expression over 100-fold while evading immune detection. This approach seeks to unlock the potential of DNA medicines for a wide range of diseases by solving historical challenges of low potency, immunogenicity, and lack of redosability.

Genetic DiseasesOncologyProtein Deficiency Disorders

Technology Platform

Tethosome platform: A non-viral DNA delivery system using LNPs to co-deliver therapeutic DNA and mRNA encoding a proprietary Tethosome protein. The protein tethers DNA to the nucleus for >100x increased expression while evading innate immune sensors (e.g., cGAS-STING), aiming for potent, durable, non-immunogenic, and redosable genetic medicines.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

The platform addresses the major historical limitations of non-viral DNA delivery, potentially unlocking a safer, more scalable, and redosable modality for genetic medicine.
Its broad applicability across gene replacement, oncology, and durable protein expression creates multiple avenues for high-value partnerships with large biopharma companies seeking next-generation gene therapy capabilities.

Risk Factors

The technology is at an early preclinical stage and requires robust in vivo validation of its potency and immune evasion claims.
The company faces intense competition in the non-viral delivery space and is dependent on securing continued venture funding or partnership deals to finance its operations and research.

Competitive Landscape

Engage Bio competes in the crowded non-viral gene delivery space, which includes companies developing novel lipid nanoparticles, polymers, and DNA/RNA constructs. Its key differentiators are the specific mechanism of nuclear tethering for enhanced potency and the engineered evasion of DNA immune sensors, which, if proven, could set it apart from alternatives that still struggle with low expression or immunogenicity.

More companies in Cell & Gene Therapy →More companies in United States →